|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee. |
| 公司地址
| 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005 |
| 電話號碼
| +1 650 242-8052 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.pacira.com |
| 員工數量
| 829 |
| Ms. Lauren Riker |
Principal Accounting Officer and Senior Vice President, Finance |
-- |
26/02/2026 |
| Ms. Kristen Marie Williams |
Chief Administrative Officer and Secretary |
美元 545.08K |
28/04/2026 |
| Mr. Shawn M. Cross |
Chief Financial Officer |
美元 525.00K |
28/04/2026 |
| Mr. Frank D. Lee |
Director and Chief Executive Officer |
美元 935.31K |
28/04/2026 |
| Dr. Jonathan Slonin, M.D. |
Chief Medical Officer |
美元 555.99K |
28/04/2026 |
| Mr. Brendan P. Teehan |
Chief Commercial Officer |
美元 497.39K |
28/04/2026 |
|
|
| Ms. Laura A. Brege |
Chairman of the Board |
28/04/2026 |
| Mr. Thomas G. Wiggans |
Independent Director |
28/04/2026 |
| Mr. Michael J. Yang |
Independent Director |
28/04/2026 |
| Dr. Mark I. Froimson, M.D. |
Independent Director |
28/04/2026 |
| Dr. Samit Hirawat, M.D. |
Independent Director |
28/01/2026 |
| Governor Christopher J. Christie |
Independent Director |
28/04/2026 |
| Mr. Frank D. Lee |
Director and Chief Executive Officer |
28/04/2026 |
| Ms. Alethia Young |
Independent Director |
28/04/2026 |
| Dr. Marcelo Bigal, M.D.,PhD |
Independent Director |
28/04/2026 |
|
|
|
|
